Murai Takehiro, Yamada Toshiyuki, Miida Takashi, Arai Katsumitsu, Endo Naoto, Hanyu Tadamasa
Niigata University School of Medicine, Asahimachi 1-757, Niigata 951-8510, Japan.
Arthritis Rheum. 2002 Jun;46(6):1683-8. doi: 10.1002/art.10327.
To examine the effects of the lipid-lowering agent fenofibrate on experimental AA amyloidosis and on serum amyloid A (SAA) levels.
Fenofibrate was administered orally in a mouse model of amyloidosis, which is induced by injections of amyloid-enhancing factor and Freund's complete adjuvant. Fenofibrate was given for 3 weeks, including a 1-week course before induction of amyloidosis. Splenic amyloid deposits were evaluated histologically, and SAA levels were measured.
Fenofibrate inhibited the formation of splenic amyloid deposits and suppressed the elevation of SAA levels. CONCLUSION; Fenofibrate inhibits experimental amyloidosis by reducing levels of the precursor SAA.
研究降脂药物非诺贝特对实验性AA淀粉样变性及血清淀粉样蛋白A（SAA）水平的影响。
在由注射淀粉样增强因子和弗氏完全佐剂诱导的淀粉样变性小鼠模型中口服给予非诺贝特。非诺贝特给药3周，包括在诱导淀粉样变性前1周的疗程。通过组织学评估脾脏淀粉样沉积物，并测量SAA水平。
非诺贝特抑制脾脏淀粉样沉积物的形成并抑制SAA水平的升高。结论：非诺贝特通过降低前体SAA水平来抑制实验性淀粉样变性。
